Triplet Immunotherapy Shows Durable Response in Relapsed Hodgkin Lymphoma

Classic Hodgkin lymphoma remains highly curable in the frontline setting, yet approximately 10 percent to 30 percent of patients eventually experience disease relapse or primary refractory status [1]. For these patients, the established standard of care involves salvage chemotherapy followed by high-dose therapy and autologous hematopoietic stem cell transplantation [2]. While the introduction of the antibody-drug conjugate brentuximab vedotin and programmed death-1 inhibitors like nivolumab has significantly improved salvage outcomes, many patients still experience progression after these therapies [3, 4]. Clinicians face a persistent challenge in managing patients who are ineligible for or wish to defer the intensive morbidity associated with transplantation [5]. To address this clinical gap, the Phase 1/2 Intergroup study E4412 (ClinicalTrials.gov identifier NCT01896999) evaluated whether intensifying immunotherapy combinations can provide a viable alternative or a more effective bridge to definitive therapy.